REPL Reports $12M Revenue, $0.05 EPS, Announces RP1 BLA Resubmission for Melanoma
Replimune Group, Inc. · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $8.69
-1.7% in 1h after detection
Post-detection moves
1h
-1.7%
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS